Possible therapeutic targets among the molecules involved in the warburg effect in tumor cells

Anticancer Research

Volumn 33, Issue 7, 2013, Pages 2855-2860

  Nam, Sung Ouk ^a   Yotsumoto, Fusanori ^a   Miyata, Kohei ^a   Shirasu, Naoto ^a   Miyamoto, Shingo ^a   Kuroki, Masahide ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Glycolytic enzymes; Oncogenes; Review; Signaling pathways; Transcription factors; Tumor suppressor genes; Warburg effect

Indexed keywords

GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOLYTIC ENZYME; HEXOKINASE; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE KINASE; SODIUM GLUCOSE COTRANSPORTER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; INTRACELLULAR SIGNALING; LIPOGENESIS; MITOCHONDRIAL RESPIRATION; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE; ONCOGENE C MYC; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; TUMOR CELL; TUMOR SUPPRESSOR GENE; UPREGULATION; VIRUS ONCOGENE; WARBURG EFFECT;

GLYCOLYTIC ENZYMES; ONCOGENES; REVIEW; SIGNALING PATHWAYS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR GENES; WARBURG EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; GLYCOLYSIS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; OXYGEN;

EID: 84883285726     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Warburg O: On respiratory impairment in cancer cells. Science 124: 269-270, 1956.
2. Pfeiffer T, Schuster S and Bonhoeffer S: Cooperation and competition in the evolution of ATP-producing pathways. Science 292: 504-507, 2001.
3. Chen Z, Lu W, Garcia-Prieto C and Huang P: The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 39: 267-274, 2007.
4. Altenberg B and Greulich KO: Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84: 1014-1020, 2004.
5. Ayala FRR, Rocha RM, Carvalho KC, Carvalho AL, Werneck da Cunha I, Lourenco SV and Soares FA: Glut 1 and Glut 3 as potential prognostic markers for oral squamous cell carcinoma. Molecules 15: 2374-2387, 2010.
6. Szablewski L: Expression of glucose transporters in cancers. Biochim Biophys Acta 1835: 164-1699, 2012.
7. Casneuf VF, Fonteyne P, Van Damme N, Demetter P, Pauwels P, de Hemptinne B, Vos M, Van de Wiele C and Petters M: Expression of SGLT1, BCL2 and p53 in primary pancreatic cancer related to survival. Cancer Invest 26: 852-859, 2008.
8. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ and Hung MC: Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13: 385-393, 2008.
9. Engelman JA and Cantley LC: A sweet new role for EGFR in cancer. Cancer Cell 13: 375-376, 2008.
10. Wright EM, Loo DD and Hirayama BA: Biology of human sodium glucose transporters. Physiol Rev 91: 733-794, 2011.
11. Wilson JE: Isozymes of mammalian hexokinase: Structure, subcellular localization and metabolic function. J Exp Biol 206: 2049-2057, 2003.
12. Pedersen PL, Mathupala S, Rempel A, Geschwind JF and Ko YH: Mitochondrial bound type II hexokinase: A key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 1555: 14-20, 2002.
13. Pelicano H, Martin DS, Xu RH and Huang P: Glycolysis inhibition for anticancer treatment. Oncogene 25: 4633-4646, 2006.
14. Sirover MA: New nuclear functions of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in mammalian cells. J Cell Biochem 95: 45-52, 2005.
15. Christofk HR, Vander Heiden MG, Wu N, Asara JM and Cantley LC: Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452: 181-186, 2008.
16. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL and Cantley LC: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233, 2008.
17. Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, Cole RN, Pandey A and Semenza GL: Pyruvate kinase M2 is a PHD3- stimulated coactivator for hypoxia-inducible factor 1. Cell 145: 732-744, 2011.
18. Goldberg MS and Sharp PA: Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med 209: 217-224, 2012.
19. Papandreou I, Cairns RA, Fontana L, Lim AL and Denko NC: HIF1 mediates adaptation to hypoxia by actively down-regulating mitochondrial oxygen consumption. Cell Metab 3: 187-197, 2006.
20. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, Royer RE, VanderJagt DL, Semenza GL and Dang CV: Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 107: 2037-2042, 2010.
21. Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324: 1029-1033, 2009.
22. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM and Thompson CB: Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factorindependent survival. Mol Cell Biol 23: 7315-7328, 2003.
23. Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism. Cell 124: 471-484, 2006.
24. Elit L: Drug evaluation: AP-23573-an mTOR inhibitor for the treatment of cancer. IDrugs 9: 636-644, 2006.
25. Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, OBrien S, Andreeff M and Giles FJ: Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12: 5165-5173, 2006.
26. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V, Borner M, Salzberg M, Ostapenko V, Illiger HJ, Behringer D, Bardy- Bouxin N, Boni J, Kong S, Cincotta M and Moore L: Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23: 5314-5322, 2005.
27. Ma WW and Jimeno A: Temsirolimus. Drugs Today 43: 659-669, 2007.
28. Marcu KB, Bossone SA and Patel AJ: myc function and regulation. Annu Rev Biochem 61: 809-860, 1992.
29. Evan GI and Littlewood TD: The role of c-myc in cell growth. Curr Opin Genet Dev 3: 44-49, 1993.
30. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB and Thompson CB: Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 105: 18782-18787, 2008.
31. Shim H, Chun YS, Lewis BC and Dang CV. A unique glucosedependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci USA 95: 1511-1516, 1998.
32. Huang LE: Carrot and stick: HIF1α engages c-Myc in hypoxic adaptation. Cell Death Differ 15: 672-677, 2008.
33. Levine AJ, Hu W and Feng Z: The P53 pathway: What questions remain to be explored? Cell Death Differ 13: 1027-1036, 2006.
34. Lee YC, Wu WJ, Li WM, Lin HH, Huang CN, Chai CY, Chang LL, Lin HL and Ke HL: Prognostic value of p53 protein overexpression in upper tract urothelial carcinomas in Taiwan. Anticancer Res 33: 1091-1098, 2013.
35. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E and Vousden KH: TIGAR, a p53- inducible regulator of glycolysis and apoptosis. Cell 126: 107-120, 2006.
36. Schwartzenberg-Bar-Yoseph F, Armoni M and Karnieli E: The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 64: 2627-2633, 2004.
37. Kawauchi K, Araki K, Tobiume K and Tanaka N: p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation. Nat Cell Biol 10: 611-618, 2008.
38. Lumachi F, Orlando R, Marino F, Chiara GB and Basso SM: Expression of p53 and Ki-67 as prognostic factors for survival of men with colorectal cancer. Anticancer Res 32: 3965-3967, 2012.
39. Zawacka-Pankau J, Grinkevich VV, Hunten S, Nikulenkov F, Gluch A, Li H, Enge M, Kel A and Selivanova G: Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: Targeting Warburg effect to fight cancer. J Biol Chem 286: 41600-41615, 2011.
40. Harris AL: Hypoxia-a key regulatory factor in tumor growth. Nat Rev Cancer 2: 38-47, 2001.
41. Semenza GL: Targeting HIF1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
42. Denko NC: Hypoxia, HIF1 and glucose metabolism in the solid tumor. Nat Rev Cancer 8: 705-713, 2008.
43. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T and Vogt PK: Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12: 363-369, 2001.
44. Martinive P, Defresne F, Quaghebeur E, Daneau G, Crokart N, Gregoire V, Gallez B, Dessy C and Feron O: Impact of cyclic hypoxia on HIF1α regulation in endothelial cells - new insights for antitumor treatments. FEBS J 276: 509-518, 2009.
45. Miyata K, Yotsumoto F, Nam SO, Kuroki M and Miyamoto S: Regulatory mechanisms of the HB-EGF autocrine loop in inflammation, homeostasis, development and cancer. Anticancer Res 32: 2347-2352, 2012.
46. Yotsumoto F, Tokunaga E, Oki E, Maehara Y, Yamada H, Nakajima K, Nam SO, Miyata K, Koyanagi M, Doi K, Shirasawa S, Kuroki M and Miyamoto S: Molecular hierarchy of heparin-binding epidermal growth factor-like growth factorregulated angiogenesis in triple negative breast cancer. Mol Cancer Res 11: 506-517, 2013